Inhibition of angiotensin II action protects rat steatotic livers against ischemia-reperfusion injury

Critical Care Medicine

Volumn 36, Issue 4, 2008, Pages 1256-1266

  Casillas Ramirez, Araní ^a   Amine Zaouali, Mohammed ^a   Massip Salcedo, Marta ^a,c   Padrissa Altés, Susagna ^a   Bintanel Morcillo, María ^a   Ramalho, Fernando ^a   Serafín, Anna ^b   Rimola, Antoni ^c   Arroyo, Vicente ^c   Rodés, Juan ^c   Roselló Catafau, Joan ^a,c   Peralta, Carmen ^a  

^a CSIC   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Angiotensin II; Bradykinin; Interleukin; Ischemia; Ischemic preconditioning; Steatotic liver

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FATTY LIVER; LIVER ISCHEMIA; LIVER PROTECTION; NONHUMAN; PRIORITY JOURNAL; RANDOMIZATION; REPERFUSION INJURY; TREATMENT OUTCOME; ZUCKER RAT;

EID: 41649116539     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31816a023c     Document Type: Article

References (43)

1. Nocito A, El-Badry AM, Clavien PA: When is steatosis too much for transplantation? J Hepatol 2006; 45:494-499
2. Peralta C, Roselló-Catafau J: The future of fatty livers. J Hepatol 2004; 41:149-151
3. Guo L, Richardson KS, Tucker LM, et al: Role of the renin-angiotensin system in hepatic ischemia reperfusion injury in rats. Hepatology 2004; 40:583-589
4. Campbell DJ: Circulating and tissue angiotensin systems. J Clin Invest 1987; 79:1-6
5. Ardaillou R: Angiotensin II receptors. J Am Soc Nephrol 1999; 10(Suppl 11):S30-S39
6. Selzner M, Clavien PA: Fatty liver in liver transplantation and surgery. Semin Liver Dis 2001; 21:105-113
7. Carrasco-Chaumel E, Rosello-Catafau J, Bartrons R, et al: Adenosine monophosphate-activated protein kinase and nitric oxide in rat steatotic liver transplantation. J Hepatol 2005; 43:997-1006
8. Gao W, Connor HD, Lemasters JJ, et al: Primary nonfunction of fatty livers produced by alcohol is associated with a new, antioxidantin-sensitive free radical species. Transplantation 1995; 59:674-679
9. Selzner M, Clavien PA: Failure of regeneration of the steatotic rat liver: disruption at two different levels in the regeneration pathway. Hepatology 2000; 31:35-42
10. Clavien PA, Selzner M, Rudiger HA, et al: A prospective randomized study in 100 consecutive patients undergoing major liver resection with versus without ischemic preconditioning. Ann Surg 2003; 238:843-852
11. Xiao XH, Allen DG: The role of endogenous angiotensin II in ischaemia, reperfusion and preconditioning of the isolated rat heart. Pflugers Arch 2003; 445:643-650
12. Randall MD, Gardiner SM, Bennett T: Enhanced cardiac preconditioning in the isolated heart of the transgenic ((mREN-2) 27) hypertensive rat. Cardiovasc Res 1997; 33:400-409
13. Diaz RJ, Wilson GJ: Selective blockade of AT1 angiotensin II receptors abolishes ischemic preconditioning in isolated rabbit hearts. J Mol Cell Cardiol 1997; 29:129-139
14. Bilbao G, Contreras JL, Eckhoff DE, et al: Reduction of ischemia-reperfusion injury of the liver by in vivo adenovirus-mediated gene transfer of the antiapoptotic Bcl-2 gene. Ann Surg 1999; 230:185-193
15. Serafin A, Rosello-Catafau J, Prats N, et al: Ischemic preconditioning affects interleukin release in fatty livers of rats undergoing ischemia/ reperfusion. Hepatology 2004; 39:688-698
16. Gohlke P, Pees C, Unger T: AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 1998; 31:349-355
17. Ishizaka N, Saito K, Noiri E, et al: Administration of ANG II induces iron deposition and upregulation of TGF-beta1 mRNA in the rat liver. Am J Physiol Regul Integr Comp Physiol 2005; 288:R1063-R1070
18. Erlich Y, Mayk A, Rosenthal T: Nitric oxide does not participate in the metabolic effects of exogenous bradykinin in fructose-fed rats. Am J Hypertens 2001; 14:3-6
19. Schafer S, Schmidts HL, Bleich M, et al: Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent. Br J Pharmacol 2004; 143:27-32
20. Yue TL, Chen J, Bao W, et al: In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 2001; 104:2588-2594
21. Sivarajah A, McDonald MC, Thiemermann C: The cardioprotective effects of preconditioning with endotoxin, but not ischemia, are abolished by a peroxisome proliferator-activated receptor-gamma antagonist. J Pharmacol Exp Ther 2005; 313:896-901
22. Serafin A, Roselló-Catafau J, Prats N, et al: Ischemic preconditioning increases the tolerance of fatty liver to hepatic ischemia-reperfusion injury in the rat. Am J Pathol 2002; 161:587-601
23. Massip-Salcedo M, Casillas-Ramirez A, Franco-Gou R, et al: Heat shock proteins and mitogen-activated protein kinases in steatotic livers undergoing ischemia-reperfusion: Some answers. Am J Pathol 2006; 168:1474-1485
24. Naik GO, Moe GW, Armstrong PW: Specific and non-specific measurements of tissue angiotensin II cascade members. J Pharm Biomed Anal 2001; 24:947-955
25. Barthelemy C, Eurin J, Lechat P, et al: The mechanism of the angiotensin-converting enzyme inhibitor quinapril is not related to bradykinin level in heart tissue. Peptides 2002; 23:1161-1169
26. Camargo CA Jr, Madden JF, Gao W, et al: Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. Hepatology 1997; 26:1513-1520
27. Freise H, Palmes D, Spiegel H: Inhibition of angiotensin-converting enzyme reduces rat liver reperfusion injury via bradykinin-2-receptor. J Surg Res 2006; 134:231-237
28. Dendorfer A, Folkers V, Klinger M, et al: Inhibition of kinin breakdown prolongs retention and action of bradykinin in a myocardial B2 receptor compartment. Br J Pharmacol 2003; 138:310-316
29. Kawasaki J, Hirano K, Hirano M, et al: Troglitazone inhibits the capacitative Ca2+ entry in endothelial cells. Eur J Pharmacol 1999; 373:111-120
30. Tang Y, Zhou L, Gunnet JW, et al: Enhancement of arachidonic acid signaling pathway by nicotinic acid receptor HM74A. Biochem Biophys Res Commun 2006; 345:29-37
31. Thai H, Wollmuth J, Goldman S, et al: Angiotensin subtype 1 receptor (AT1) blockade improves vasorelaxation in heart failure by up-regulation of endothelial nitric-oxide synthase via activation of the AT2 receptor. J Pharmacol Exp Ther 2003; 307:1171-1178
32. Widder J, Behr T, Fraccarollo D, et al: Vascular endothelial dysfunction and superoxide anion production in heart failure are p38 MAP kinase-dependent. Cardiovasc Res 2004; 63:161-167
33. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995; 345:669-685
34. Rutherford JD, Pfeffer MA, Moye LA, et al: Effects of captopril on ischemic events after myocardial infarction: Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation 1994; 90:1731-1738
35. Jeserich M, Ihling C, Allgaier HP, et al: Acute liver failure due to enalapril. Herz 2000; 25:689-693
36. Romero-Gomez M, Miralles EJ, Garcia Diaz E, et al: Hepatotoxicity induced by fosinopril. Hepatology 2001; 35:309-310
37. Pitt B, Segal R, Martinez FA, et al: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349:747-752
38. Yang Z, Bove CM, French BA, et al: Angiotensin II type 2 receptor overexpression preserves left ventricular function after myocardial infarction. Circulation 2002; 106:106-111
39. Molavi B, Chen J, Mehta JL: Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK. Am J Physiol Heart Circ Physiol 2006; 291:H687-H693
40. Liu YH, Yang XP, Sharov VG, et al: Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: Role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997; 99:1926-1935
41. Siragy HM, De Gaspero M, El-kersh MA, et al: Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP. Hypertension 2001; 38:183-186
42. Soden M, Klett C, Hasmann T, et al: Angiotensinogen: An acute-phase protein? Hypertension 1994; 23:I126-I130
43. Ron D, Brasier AR, Wright KA, et al: The permissive role of glucocorticoids on interleukin-1 stimulation of angiotensinogen gene transcription is mediated by an interaction between inducible enhancers. Mol Cell Biol 1990; 10:4389-4395